A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a dose escalation study and will be the first to administer SY-5609 alone to humans
with select advanced solid tumors and in combination with Fulvestrant to patients with HR
positive, HER2-negative breast cancer.